Form 8-K Spark Therapeutics, Inc. For: Oct 05

Go back to Form 8-K Spark Therapeutics, Inc. For: Oct 05

Chardan Capital Says to Buy Spark Therapeutics (ONCE) Peers Following SPK-RPE65 Results (AAVL) (VBLT)

October 5, 2015 10:34 AM EDT

Chardan Capital recommends to buy several biotech names after Spark Therapeutics (NASDAQ: ONCE) announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs) earlier Monday.

Gbola Amusa... More